DBS Group , Southeast Asia's biggest bank, has raised $2 billion through a multi-tranche U.S. dollar senior bond issuance for ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

The Equities Market Review Group has issued its first set of measures to strengthen the competitiveness of Singapore’s equities markets. The ...

Singapore family offices and hedge funds along with Hong Kong institutions are bullish on the ASX healthcare sector. ... Read ...

Together with the retail malls, LREIT’s Singapore portfolio which accounts for approximately 90% 1 of the total portfolio by valuation, has delivered good rental growth. As at 31 December 2024, its ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Together with the retail malls, LREIT's Singapore portfolio which accounts for approximately 90% 1 of the total portfolio by valuation, has delivered good rental growth. As at 31 December 2024 ...

UK drugmaker GSK was one of the companies spending money away from the UK this month, agreeing to acquire US-based biotech IDRx for $1.15bn to bolster its oncology portfolio. The deal follows GSK’s ...